CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct” Cancer advocates express concern about comments that signal trouble for accelerated approval

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?

Last month, FDA withdrew a proposed rule for standardized asbestos testing in talc-based cosmetics. The proposed rule, introduced in Nov. 2024 and withdrawn Nov. 2025, was mandated by the Modernization of Cosmetics Regulation Act of 2022 or MoCRA.

December 17, 2025

Regulatory News

FDA withdraws proposed rule for asbestos testing in talc-based cosmetics
It’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation

FDA has withdrawn a proposed rule that called for standardized testing for detecting and identifying asbestos in talc-containing cosmetic products.

December 12, 2025

Vol.51 No.45

By Claire Marie Porter

Cancer Policy

Former FDA Commissioner Scott Gottlieb speaks out against CDC vaccine panel

Scott Gottlieb, a former FDA commissioner, said a recent decision by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices’ to change its recommendation for when children should receive the hepatitis B vaccine is another sign of the ACIP’s diminished credibility as a scientific authority.

White House directs HHS and CDC to align childhood vaccine recommendations with “best practices from peer, developed countries”

In a Dec. 5 memo, President Donald Trump directed the HHS secretary and the CDC director to “align the U.S. core childhood vaccine recommendations with best practices from peer, developed countries.”

HHS issues AI strategy for internal agency operations

HHS has issued its AI strategy—“the first step” in making a “whole-of-department transformation” towards the use of artificial intelligence in public health, health care delivery, biomedical research, human services, and agency operations.

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

After three weeks of brutal combat, Richard Pazdur decided that he has had enough.

December 05, 2025

Vol.51 No.44

By Paul Goldberg

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”

Cancer advocates express concern about comments that signal trouble for accelerated approval

YOU MAY BE INTERESTED IN

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?

FDA withdraws proposed rule for asbestos testing in talc-based cosmetics
It’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation

Former FDA Commissioner Scott Gottlieb speaks out against CDC vaccine panel

White House directs HHS and CDC to align childhood vaccine recommendations with “best practices from peer, developed countries”

HHS issues AI strategy for internal agency operations

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

Renew today!

Subscriber content

Never miss an issue!

Login

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”

Cancer advocates express concern about comments that signal trouble for accelerated approval

YOU MAY BE INTERESTED IN

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?

FDA withdraws proposed rule for asbestos testing in talc-based cosmeticsIt’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation

Former FDA Commissioner Scott Gottlieb speaks out against CDC vaccine panel

White House directs HHS and CDC to align childhood vaccine recommendations with “best practices from peer, developed countries”

HHS issues AI strategy for internal agency operations

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulationsBIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

Never miss an issue!

Login

FDA withdraws proposed rule for asbestos testing in talc-based cosmetics
It’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship”